Kyruus, Boston-based analytics and scheduling software provider for healthcare systems, pulled in $30 million, led by Bay-area private equity firm Francisco Partners.
This new investment follows on the heels of the company's Series D round worth $42 million late last year, bringing its funding total to $155 million since its founding in 2010.
“We anchored our platform on the principle that healthcare organizations could better match patients to the right providers and care settings through a data-driven approach to routing and scheduling," said Kyruus CEO Graham Gardner in a statement. "This ability to connect patients to the appropriate care – across virtual and in-person appointments – has never been more critical. We are excited to work with the team at Francisco Partners to accelerate our impact through a range of strategic opportunities.”
The coronavirus pandemic has not affected all industries alike. Startups in telehealth and biotech, for instance, have seen their business propel during this time. Just as the rising tide lifts all boats, capital infusion in biotech has been on a surge. This is true not only for public companies, including Gilead Sciences and Cambridge-based Moderna Therapeutics, but also for venture-backed private startups.
In May alone, three biotech companies and a health tech startup launched with significant funding. This is in addition to later-stage companies raising $100 million-plus rounds, including Atea Pharmaceuticals' $215 million in Series D funding, and Lowell startup Rapid Micro Biosystems' $120 million. And following a whopping Series C round of $194 million, Boston-based telemedicine company Amwell confidentially filed for an IPO.
Kyruus said the additional funding will help the company expand its platform, broaden its footprint with health systems, and expand to new markets.
